 |
|
|
|
 |
|
|
| Article 1 to 10 out of 17 concerning Eli Lilly and Company
|
-
Galapagos announces first milestone in osteoporosis collaboration with Lilly
(07/21/2008)
Galapagos NV announced that it has reached the first milestone in its osteoporosis collaboration with Eli Lilly and Company, triggering a payment of EUR1 million from Lilly.In December 2007, Lilly and Galapagos initiated a program to develop new ...
-
Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease
(04/03/2008)
Late-stage IDENTITY study of once-daily, oral agent is now enrolling patients
Eli Lilly and Company has announced the start of a Phase III clinical trial studying LY450139, an investigational gamma secretase inhibitor for the treatment of mild to moderate Alzheimer's disease. LY450139 is being tested to see if it can slow the ...
-
Gastrotech signs licensing agreement with Eli Lilly following positive clinical data on compound for Irritable Bowel Syndrome
(01/30/2008)
Gastrotech Pharma, a biopharmaceutical R&D company with a focus on the medical applications of gastrointestinal hormones, has signed an agreement with Eli Lilly and Company (Indianapolis, USA) to in-license a Lilly compound (now named GTP-010), an ...
-
Galapagos extends drug discovery collaboration with Lilly in nuclear hormone receptor research
(01/16/2008)
Galapagos NV announced that its service division BioFocus DPI has extended its drug discovery agreement with Eli Lilly and Company until end 2008. Under the terms of the agreement, BioFocus DPI will screen certain compounds as provided by Lilly ...
-
Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel
(11/06/2007)
Duke Clinical Research Institute to lead multinational study with investigational compound
A large Phase III clinical trial is anticipated to begin in the second quarter of 2008 to compare the effects of prasugrel, an investigational oral antiplatelet agent, against clopidogrel (Plavix(R)/Iscover(R)) in medically managed patients with ...
-
Chi-Med Announces Drug Discovery and Development Agreement with Eli Lilly and Company
(08/22/2007)
Chi-Med, the Hutchison Whampoa backed pharmaceutical and healthcare Group, announced that its wholly-owned drug R&D subsidiary, Hutchison MediPharma R&D Limited ("Hutchison MediPharma"), has entered into a drug discovery and development agreement ...
-
Researchers Identify Genetic Mutation That May Alter Patients' Response to Cancer Therapeutics
(07/06/2007)
Recurring mutation found in breast, colorectal and ovarian cancers
Researchers from Eli Lilly & Company and the Phoenix-based Translational Genomics Research Institute (TGen) announced finding a novel recurring mutation of the gene AKT1 in breast, colorectal and ovarian cancers. The altered form of AKT1 appears to ...
-
Lilly Expands Drug Discovery Efforts in Singapore
(03/28/2007)
Broader Research Focus Will Leverage Local and Regional Talent
Eli Lilly and Company announced a USD $150 million expansion, over the next five years, of its state-of-the-art drug discovery research activities at the Lilly Centre for Systems Biology (LSB). The project, a partnership with the Singapore Economic ...
-
Lilly Expands Biotech Capabilities to Match Expanding Biotech Pipeline
(10/25/2006)
First phase of $560 million complex completed
Eli Lilly and Company announced completion of the first phase of a $560 million expansion to its biotech complex in Indianapolis. The investment is part of a $1 billion effort to strengthen and build the company's biotechnology drug research and ...
-
Lilly and Biosite to Collaborate on Clinical Trial Using Tailored Xigris Therapy
(03/22/2006)
Trial to Study Use of Biomarker to Better Define Xigris Patients and Treatment Response
Eli Lilly and Company and Biosite® Incorporated announced the two companies have signed an agreement to collaborate in connection with a clinical trial employing a tailored therapy strategy for Lilly's severe sepsis drug, Xigris® (drotrecogin alfa ...
|
|
|
|
|
Top